-continued

Cys Ser Asp Leu Glu Val Tyr Phe Cys His Leu Asp Ile Ile Trp
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(i i) MOLECULE TYPE: peptide

(i x) FEATURE:
(A) NAME/KEY: Disulfide-bond
(B) LOCATION: 1..9

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Cys Ser Asn Lys Gln Val Tyr Phe Cys His Leu Asp Ile Ile Trp
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(i i) MOLECULE TYPE: peptide

(i x) FEATURE:
(A) NAME/KEY: Disulfide-bond
(B) LOCATION: 4..8

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Asp Lys Glu Cys Val Tyr Phe Cys His Leu Asp Ile Ile Trp
1 5 10

We claim:

1. A compound of formula I

$$AA^1—R—R^1—R^2—AA^{1a}—AA^2—AA^3—AA^4—AA^3—AA^3—AA^5 \quad \text{I}$$

wherein

AA_1 is



wherein

X is

hydrogen,
alkyl,
alkenyl,
alkynyl,
cycloalkyl,
heterocycloalkyl,
aryl, or
heteroaryl,

n is zero or an integer of 1 or 2,

R^3 is —S—R^4, wherein R^4 is as defined hereinafter,

wherein R^4 is as defined hereinafter,

—$C(CH_3)_2$—S—R^4, wherein R^4 is covalently linked to AA^{1a} through a disulfide bridge,



wherein X is as defined above, X^1 is hydrogen or Asp-Lys-Glu and n and R^3 are as defined above,



wherein X, n, and R^3 are as defined above, or